Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib in Treatment Naïve Chronic Lymphocytic Leukemia (CLL)
NCT04163718Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of umbralisib in chronic lymphocytic leukemia (CLL), sponsored by Moffitt Cancer Center. Started Nov 2019; status: terminated.
02
Drugs
umbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04163718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163718.